Semaglutide: the original single-pathway peptide

Before tirzepatide's dual action and Triple R's multi-pathway action, there was semaglutide — the compound that turned a single metabolic pathway from a laboratory curiosity into one of the most studied targets in metabolic science. Understanding it is the natural starting point for the whole modern field.

A single, well-characterised pathway

Semaglutide is a synthetic analogue of a gut-derived signalling hormone released in response to food. It is studied as a single-pathway peptide — a molecule that engages one pathway, central to glucose and appetite signalling in laboratory models. Its single-pathway focus is what makes it the reference point against which dual- and multi-pathway peptides are compared.

Why it became the reference compound

In the published research literature, semaglutide has been associated with pronounced effects on metabolic markers and body-weight regulation in study models, alongside a long duration of action. Our articles on gut-derived metabolic signalling and metabolic research peptides place it beside tirzepatide and Triple R in the research lineage.

Structure and stability

Semaglutide's backbone carries amino-acid substitutions and a fatty-acid chain that slow its breakdown — modifications that give it a far longer half-life than the native hormone. Our companion article on why modified peptides last longer explains the design. It is supplied as a lyophilised (freeze-dried) powder, the most stable form.

Handling and reconstitution

Semaglutide is reconstituted with bacteriostatic water before use in research. Our reconstitution and storage guide covers the correct method, and every Vela order ships with a free 3 mL vial of bacteriostatic water.

Documented quality

Because semaglutide is such an active research subject, verified identity and purity matter. Every Vela batch is supplied with a certificate of analysis issued within six months of sale.